Advocacy
Stop censoring CBD: New cannabis coalition aims to prevent censorship
A US campaign has been launched with the aim of preventing the censorship of CBD products. They are aiming for 10,000 signatures by the end of August.
A campaign from a new cannabis industry coalition has been launched with the aim of preventing censorship of CBD products.
The Cellular Telecommunications and Internet Association (CTIA), a non-profit trade organisation that monitors US content relating to sex, hate, alcohol, firearms and tobacco (collectively known as SHAFT), recently added CBD to its list.
As a result, CBD companies are no longer permitted to use SMS messaging for marketing purposes. In response to this decision, a number of cannabis companies have launched the campaign Stop Censoring CBD, led by CBD brand Prima.
The movement has built a group of advocates, who are lobbying for the unlocking of the industry via a Change.org petition, aiming for 10,000 signatures by August.
The founding members of the movement include top CBD brands such as Plant People, Svn Space, Foria Wellness and Papa and Barkley among many others. Other brands include Onda Wellness, oHHo and Plant Society.
Image credits: Prima CBD #FreeCBD campaign
Censoring CBD through Text marketing
Text messaging is a form of direct communication for many CBD wellness companies to help educate consumers about their products, and the benefits of CBD generally; as well as managing customer services.
Upon completion of the petition, Stop Censoring CBD hopes it will encourage lawmakers to co-sponsor and pass the Hemp Access and Consumer Safety Act (S. 1698). This, it says, will establish legal and regulatory pathways for the nationwide sale of hemp-derived extract products.
In 2018, hemp was removed from the US federal government’s list of controlled substances. But clear FDA guidelines or policies regarding hemp-derived CBD, have yet to be published. The coalition also plans to put pressure on the FDA to move forward with regulatory actions that would separate hemp-derived CBD from other CBD.
It believes this will collectively create a framework for companies to ensure compliance and protect consumers with clear guidelines and standards for safety, labelling, potency, growing practices, manufacturing and communications for all products.
Read more: Irish campaigner responds to doctors proposal to shun MCAP programme
-
News6 months agoEurope’s first legal cannabis dispensaries to open under sixth Swiss pilot
-
Science5 months agoMedical cannabis doesn’t impair cognitive function – study
-
Industry6 months agoFirst Jersey-grown medicinal cannabis product to hit UK market
-
News6 months agoFive years of medical cannabis, five NHS prescriptions – how did we get here?
-
News5 months agoJapan takes major step towards cannabis reform
-
Health4 months agoUK data links medical cannabis to improvements in ADHD patients
-
News5 months agoMPs call for children with epilepsy to get medical cannabis on NHS
-
Health3 months agoUK researchers publish first findings on cannabis and Long COVID
